{
    "id": "correct_subsidiary_00122_2",
    "rank": 60,
    "data": {
        "url": "https://www.xocpharma.com/",
        "read_more_link": "",
        "language": "en",
        "title": "Therapies for Migraine Prevention",
        "top_image": "https://www.xocpharma.com/themes/default/images/favicon.ico",
        "meta_img": "https://www.xocpharma.com/themes/default/images/favicon.ico",
        "images": [
            "https://www.xocpharma.com/themes/default/images/logo.svg",
            "https://www.xocpharma.com/file.cfm/1/docs/xoc_pipeline_021320.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Xoc Pharmaceuticals is an early-stage, biopharmaceutical company focused on the development of novel oral therapies for migraine prevention and dopamine agonism for Parkinson’s disease management.",
        "meta_lang": "",
        "meta_favicon": "/themes/default/images/favicon.ico",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "Scott Borland\n\nPresident & Chief Executive Officer\n\nMr. Borland is a Co-founder of Xoc Pharmaceuticals and has more than 20 years of experience in drug delivery, including medical devices and drug-device combination products. Most recently, Mr. Borland served as Senior Vice President of the Neurology Franchise at MAP Pharmaceuticals, which was acquired by Allergan in 2013. Mr. Borland was responsible for all development activities related to the company’s lead product, including design engineering and manufacturing, regulatory activities and manufacturing scale-up. Prior to MAP, Mr. Borland held senior management positions at Capnia, Inc., where he was Vice President of Engineering and Operations, and Aerogen, Inc., where he was Senior Director, Engineering and Operations. He has held a series of other positions in the medical device, drug delivery, and computer hardware industries with Therics, Inc., Topaz Technologies, and Applied Magnetics and was previously a Visiting Scientist at the Massachusetts Institute of Technology. Mr. Borland holds an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Materials Science and Engineering from the University of Arizona.\n\nMiguel Guzman, Ph.D.\n\nVice President, Technical Operations & Product Development\n\nDr. Guzman is a Co-founder of Xoc Pharmaceuticals and has more than 20 years of experience in pharmaceutical and biotech product research and development, process validation, product launch and life-cycle management. Most recently, Dr. Guzman served as Director of Technical Operations at MAP Pharmaceuticals, where he was responsible for overseeing and managing chemical and manufacturing controls activities for the company’s lead product. Prior to MAP, he held multiple technical leadership roles, with increasing levels of responsibility, at 3M Pharmaceuticals and 3M Drug Delivery Systems in product development and marketed product support. Dr. Guzman earned his Ph.D. in Analytical Chemistry from University of Washington and received his B.Sc. in Chemistry from Kentucky Wesleyan College.\n\nThomas Armer, Ph.D.\n\nConsulting Chief Technology Officer\n\nDr. Armer has over 25 years of experience in the pharmaceutical and drug delivery industry. Dr. Armer co-founded MAP Pharmaceuticals in 2003 and served as its Chief Scientific Officer and member of the Board of Directors until the company was acquired by Allergan in 2013. Prior to MAP, Dr. Armer served as Vice President of Pulmonary Delivery Systems and later as Chief Scientific Officer at Sheffield Pharmaceuticals, Inc., a biopharmaceutical company focused on development of pharmaceuticals for pulmonary delivery. Dr. Armer also held a series of senior management and product development positions at the Novon Products Group, a division of Warner-Lambert, and Aeroquip Vickers Corporation. Dr. Armer received a Ph.D. in chemical engineering from Tulane University and a B.S. in chemical engineering from New Mexico State University.\n\nRobert S. Fishman, M.D.\n\nConsulting Chief Medical Officer\n\nDr. Fishman has over 20 years of experience in product development spanning drugs and drug-device combinations. He has served as our Chief Medical Officer since February 2019. From 2015 to 2019, Dr. Fishman was Chief Medical Officer at Corcept Therapeutics, where he led programs in endocrine/metabolic diseases and in oncology, including the advancement of relacorilant to Phase 3 for the treatment of Cushing syndrome. From 2012 to 2015, he was Senior Vice President of Clinical Development at InterMune (acquired by Roche) where he led the final stage of the clinical development of pirfenidone (Esbriet®) for the treatment of idiopathic pulmonary fibrosis. Prior to InterMune, he was Vice President of Clinical Development at Alexza Pharmaceuticals and led the final stage of the clinical development of inhaled loxapine (ADASUVE®), a drug/device combination for the acute treatment of agitation associated with schizophrenia or bipolar I disorder. Before that, he held clinical development positions at Heartport, Aerogen and Anthera Pharmaceuticals. Dr. Fishman trained in internal medicine at Deaconess Hospital, Boston, completed a fellowship in pulmonary and critical care medicine at Massachusetts General Hospital, and began his career as a member of the Stanford University pulmonary medicine faculty. He serves as a teaching attending physician in the Stanford pulmonary fellows’ clinic at Palo Alto Veterans Administration Medical Center. He earned an A.B. in Biology from Harvard University and an M.D. from Stanford University School of Medicine.\n\nLisa Borland\n\nMarketing, Corporate Communications & Infrastructure Operations\n\nMs. Borland is a Co-founder of Xoc Pharmaceuticals and has over 13 years of experience in the pharmaceutical and drug delivery industry across marketing, regulatory, public and investor relations. Most recently, she has been a consultant to various small to mid-size biotech companies in the area of Corporate Communications. Previously, Ms. Borland was Senior Manager of Corporate Communications and Investor Relations at MAP Pharmaceuticals where she was responsible for managing external corporate communications and presentation of the company’s brands, products and activities. Prior to MAP, Ms. Borland held positions at Aerogen, Inc. in Marketing, where she was co-manager of one of the key marketing programs, and Regulatory, where she was a part of the combination product team that developed and submitted the Investigational New Drug application (IND) for an aerosolized antibiotic for treatment of ventilator associated pneumonia. Ms. Borland received a B.A. in Art History and Studio Art from Dartmouth College."
    }
}